Interferons have long occupied a privileged place in immunology. These pro-inflammatory signaling proteins act as molecular alarms, rushing to the site of a nascent cancer and recruiting specialized immune cells such as T cells and B cells to seek out and destroy malignant tissue. This early interferon response is widely regarded as a critical and powerful component of the body’s natural cancer surveillance. Yet clinicians and researchers have repeatedly observed a troubling pattern: in established tumors, interferon signaling that persists too long often correlates with worse outcomes, immune evasion, and resistance to checkpoint blockade therapies such as anti-PD1. Why a protein that begins as an anti-cancer warrior becomes a tumor’s accomplice has remained one of the field’s most stubborn open questions.

The Salk team, led by senior author Gerald Shadel, professor and holder of the Audrey Geisel Chair in Biomedical Science, approached the mystery from an unusual angle—the mitochondria. Shadel’s laboratory has spent years investigating how these cellular powerhouses communicate with the immune system, most notably through their discovery that mitochondria can provoke interferon responses by releasing their genetic material, mitochondrial DNA, into the rest of the cell, where it is perceived as a foreign invader. For the new study, the researchers deliberately inverted this question. Rather than asking how mitochondria shape interferon signaling, they asked how sustained interferon exposure reshapes mitochondrial function—and whether that remodeling could hold the key to the paradox of pro-tumor interferon activity.

To find out, the team exposed melanoma cells in the laboratory to type I or type II interferons for either brief, acute periods or extended, chronic periods. The differences were dramatic. Acute interferon exposure left the mitochondria largely unscathed, but chronic exposure produced measurable deterioration in the organelles’ energetic function. When the researchers then transferred these chronically exposed melanoma cells into a mouse model, they made an unexpected and consequential observation: chronic interferon II exposure did not slow tumor growth—it enhanced it. The finding provided a clean experimental demonstration that the duration of interferon signaling, not merely its presence, determines whether it helps or harms the host in the fight against cancer.

Digging into the cellular machinery behind this switch, the researchers uncovered a previously unknown pathway that begins deep inside the mitochondria. Chronic type II interferon exposure causes mitochondrial RNA, or mtRNA, to escape the confines of the organelle and leak into the main body of the cell. Sensing this misplaced genetic material, the cell’s innate immune surveillance systems interpret it as evidence of viral invasion and respond by producing type I interferon—a second, distinct interferon family. Type I and type II interferons then act in concert to drive up the levels of an enzyme called cyclooxygenase 2, which in turn increases the synthesis of a bioactive lipid known as prostaglandin E2. This lipid messenger, long associated with inflammation and immunosuppression in tumors, effectively flips the tumor microenvironment from a state of immune attack to one of immune tolerance.

The identification of prostaglandin E2 as the linchpin of this pathway immediately suggested a therapeutic test. If this lipid signal was the agent responsible for damping down the immune response, the researchers reasoned, then preventing melanoma cells from manufacturing it might restore the immune system’s ability to see and attack the cancer. The stakes of this question extend well beyond basic biology. Anti-PD1 immunotherapies—among the most widely used cancer treatments in the world today—work by blocking a signal that cancer cells deploy to keep immune cells at bay. But tumors frequently deploy additional, independent immunosuppressive pathways, allowing them to continue growing even in patients receiving anti-PD1 treatment. Understanding and disabling those alternative escape routes is one of the most urgent challenges in modern oncology.

“Chronic interferon exposure is a major factor in immunotherapy resistance,” said Melissa Johnson, a graduate student researcher in Shadel’s laboratory and first author of the study. “We wondered whether cancer cells that have become resistant to anti-PD1 therapy were upregulating the immunosuppressive mitochondria-centered pathway we identified, and whether that pathway is a viable target for combating immunotherapy resistance.” The team’s experimental results answered that question with unusual force. When the researchers blocked prostaglandin E2 synthesis in mouse melanoma cells, the immune system’s capacity to recognize and destroy the cancer was restored. More remarkably, blocking the lipid signal reversed resistance to anti-PD1 therapy itself: in nine out of ten mice, tumors that had previously shrugged off immunotherapy regressed completely and did not return.

The completeness and durability of those responses set the findings apart from typical incremental advances in tumor immunology. Rather than merely slowing tumor growth, eliminating the prostaglandin E2 signal appeared to reawaken a sustained, effective anti-tumor immune attack—suggesting that the mitochondria-to-prostaglandin pathway is not simply one suppressive mechanism among many, but a genuine molecular switch governing whether the tumor microenvironment invites or repels immune destruction. In the melanoma model, flipping that switch off was sufficient to transform an immunologically “cold,” therapy-resistant tumor back into one the immune system could eradicate.

The implications for future cancer treatment are considerable. The study points to a potential strategy for sustaining the immune system’s assault on tumors by intervening in the mitochondrial signaling axis rather than, or in addition to, checkpoint blockade. Because the pathway is cell-autonomous—operating within the tumor cells themselves—it offers a target that may complement existing immunotherapies and provide an option for patients whose cancers have exhausted the benefits of anti-PD1 agents. While the work remains at the preclinical stage in mouse models, the researchers emphasize that the pathway’s components, from mtRNA release to cyclooxygenase 2 activity to prostaglandin E2 production, represent a series of druggable nodes that could each be targeted therapeutically. Existing drugs that inhibit cyclooxygenase enzymes, for example, raise the possibility of repurposing well-characterized compounds to disrupt the pathway at its enzymatic core.

Beyond its immediate translational promise, the work carries a broader conceptual message for cancer biology: mitochondrial signaling cannot be treated as a background housekeeping function when modeling how tumors interact with the immune system. Shadel’s team demonstrated that a signaling molecule long classified purely as an immune modulator exerts direct, physical effects on mitochondrial integrity within cancer cells, and that those effects feed forward into an inflammatory lipid axis with decisive immunological consequences. The finding enriches the field’s understanding of how the immune system attacks cancer cells but can also be stymied by other factors in the tumor environment, and it makes a compelling case for integrating mitochondrial signaling functions into the design and interpretation of cancer studies.

For a question that has puzzled the field for decades—why the immune system sometimes helps tumors grow—the Salk team has delivered not just an explanation but a roadmap. Chronic interferon II drives mitochondrial RNA out of its organelle home, ignites a type I interferon response inside the tumor cell itself, amplifies cyclooxygenase 2, floods the microenvironment with prostaglandin E2, and thereby blindfolds the immune system at the very moment it should be striking. Cut the pathway at its lipid endpoint, and the blindfold falls away. The research was funded by the National Institutes of Health alongside private philanthropic support from the Glenn Foundation for Medical Research, the Cancer Research Institute, the NOMIS Foundation, and others, and the team included contributors spanning immunology, metabolism, and epigenetics—an interdisciplinary breadth that mirrors the pathway’s own reach across cellular compartments. As immunotherapy resistance continues to challenge clinicians worldwide, this mitochondria-centered mechanism offers a durable answer to a longstanding mystery and, potentially, a powerful new lever to pull in the clinic.

Palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has been heralded for its ability to halt cell cycle progression, effectively suppressing tumor proliferation in hormone receptor-positive breast cancer. When paired with endocrine therapy, which targets hormone-driven tumor growth, this combination forms a cornerstone of current treatment standards for early breast cancer. However, the NeoRHEA trial’s results suggest a more complex biological narrative, wherein these therapies may inadvertently suppress the immune system’s ability to combat cancer cells.

The adaptive immune system, comprised primarily of T and B lymphocytes, plays an integral role in recognizing and eliminating malignant cells. It serves as the body’s precision-guided missile system, adapting and responding dynamically to the evolving landscape of cancer antigens. The NeoRHEA study meticulously analyzed the immune landscape before and after treatment, revealing a notable decline in the activity and abundance of tumor-specific cytotoxic T cells following the administration of palbociclib and endocrine therapy.

Mechanistically, the immunosuppressive effect observed may be linked to palbociclib’s impact on the cell cycle of proliferating immune cells. Since CDK4/6 pathways regulate not only cancer cell division but also lymphocyte expansion, the drug’s inhibitory action can unintentionally dampen immune cell proliferation. Additionally, endocrine therapy’s modulation of estrogen signaling might further alter immune cell functionality and cytokine profiles, contributing to a less hostile environment for residual tumor cells.

The ramifications of these findings extend beyond academic curiosity, raising pressing questions about the long-term efficacy of current standard-of-care regimens. If the immune system, particularly the adaptive arm, is compromised, the patient’s ability to maintain immunological surveillance and respond to microscopic residual disease may be reduced. This scenario could potentially lead to higher recurrence rates or diminished responses to subsequent immunotherapies.

The NeoRHEA phase 2 study deployed advanced immunophenotyping and functional assays on tumor biopsies and peripheral blood samples from patients undergoing the combined treatment. These robust methodologies allowed for unprecedented resolution in mapping immune cell dynamics in real-time. Such detailed immune profiling is critical in unveiling treatment-induced alterations that would otherwise remain obscure in clinical outcome-focused studies.

Intriguingly, the study also hints at differential immunomodulatory effects depending on the timing and sequencing of therapies. Early initiation of palbociclib alongside endocrine agents seemed to exert the most pronounced suppression on effector T cell populations. This temporal aspect opens avenues for potential treatment optimization, including staggered or intermittent dosing schedules designed to preserve immune competence while maintaining antitumor efficacy.

Furthermore, the NeoRHEA findings underscore the complexity of tumor-host interactions and the necessity for integrative therapeutic strategies. The immune system cannot be viewed in isolation but rather as a dynamic partner in cancer control. As such, emerging treatment regimens might need to incorporate immune-supportive measures or agents that can mitigate the unintended immunosuppressive effects of cytostatic drugs.

Current clinical trials exploring the combination of CDK4/6 inhibitors with immune checkpoint inhibitors may need to reconsider their design in light of these results. If palbociclib dampens T cell activity, its concurrent use with immunotherapeutics that rely on robust cellular immunity might yield suboptimal outcomes. Future trials could explore dose adjustments or sequential therapy strategies to enhance synergy between targeted therapy and immunotherapy.

The NeoRHEA study also serves as a compelling call to action for the oncology research community to delve deeper into the immunological consequences of non-traditional immune modulators. While chemotherapy and radiotherapy have well-established immunosuppressive profiles, targeted therapies are only now being recognized for their nuanced immune interactions, necessitating a more comprehensive approach to therapeutic development.

Moreover, the implications of these findings are particularly pertinent in the context of personalized medicine. Biomarkers predicting which patients are most vulnerable to adaptive immune suppression during palbociclib and endocrine treatment could inform treatment selection and tailoring. This approach aligns with the broader shift towards precision oncology, where the molecular and immunological landscape of the tumor dictates therapy.

In conclusion, the NeoRHEA phase 2 study introduces a paradigm shift in understanding early breast cancer treatment dynamics. It highlights a paradox where therapies aimed at slowing tumor growth may simultaneously undermine the body’s own immune defenses—a revelation that challenges oncologists to rethink therapeutic strategies. Balancing anti-proliferative efficacy with preservation of immune function will be essential in the quest to improve long-term patient outcomes.

As this landscape evolves, novel combination regimens integrating immune potentiators or immune-sparing alternatives to palbociclib might emerge. Ongoing research inspired by the NeoRHEA findings will undoubtedly lead to more nuanced treatment protocols, potentially involving intermittent dosing or pairing with immunomodulatory agents to restore adaptive immunity.

The study’s insights pave the way for a new era where immune monitoring becomes integral to cancer therapy management. Incorporating routine immune profiling in clinical practice could help detect immunosuppression early, guiding timely interventions that sustain immune vigilance against cancer resurgence.

Ultimately, the NeoRHEA phase 2 trial exemplifies the power of translational research in uncovering hidden complexities within established treatments. By shedding light on the unintended immunological consequences of palbociclib and endocrine therapy, it emphasizes the imperative for a holistic approach to cancer care—one that harmonizes cytostatic control with immune empowerment.

Subject of Research:
Early breast cancer, palbociclib and endocrine therapy combination effects on adaptive anti-tumor immunity.

Article Title:
Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study.

Article References:
Papagiannis, A., Majjaj, S., Duhoux, F.P. et al. Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study. Nat Commun (2025). https://doi.org/10.1038/s41467-025-66590-2

Image Credits: AI Generated